All In Biotech

Drug Trial Radar · NCT02872714

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations - (FIGHT-201)

Last checked: Nov 19, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 263 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

263

Actual

Start

Jan 12, 2017

Primary completion

Feb 1, 2022

Study completion Feb 1, 2022

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Aug 19, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the overall response rate (ORR) of pemigatinib as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring FGF/FGFR alterations.

Conditions

  • UC (Urothelial Cancer)

Interventions

  • pemigatinibDrug

    Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy.

  • pemigatinibDrug

    Pemigatinib once a day by mouth continuously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) in Participants With FGFR3 Mutations or Fusions on a CD RegimenTime frame: up to 1138 days

Locations

96 sites in 11 countries. Site status is shown where the registry gives one.

  • Arizona Oncology Associates (Wilmot)

    Tucson, Arizona

  • Sharp Memorial Hospital

    San Diego, California

  • UCSF Helen Diller Family Comprehensive Care Center

    San Francisco, California

  • Rocky Mountain Cancer Centers

    Boulder, Colorado

  • Calaway-Young Cancer Center at Valley View Hospital

    Glenwood Springs, Colorado

  • Mount Sinai Medical Center

    Miami Beach, Florida

  • Florida Hospital Cancer Institute

    Orlando, Florida

  • Emory University School of Medicine

    Atlanta, Georgia

  • University of Maryland, Greenebaum Cancer Center

    Baltimore, Maryland

  • Lahey Clinic Inc. - PARENT ACCOUNT

    Burlington, Massachusetts

  • Minnesota Oncology Hematology, P.A.

    Woodbury, Minnesota

  • GU Research Network

    Omaha, Nebraska

  • TRIO - Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • New York Oncology Hematology, P.C.

    Albany, New York

  • Northwell Cancer Institute

    New Hyde Park, New York

  • University of Rochester

    Rochester, New York

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Oncology Hematology Care, Inc.

    Cincinnati, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • Compass Oncology the Northwest Cancer Specialists

    Tualatin, Oregon

  • St. Luke's Hospital

    Bethlehem, Pennsylvania

  • VA Pittsburgh Healthcare System

    Pittsburgh, Pennsylvania

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Texas Oncology, P.A. - Austin

    Austin, Texas

  • Texas Oncology - Baylor Charles A. Sammons

    Dallas, Texas

  • Texas Oncology

    Houston, Texas

  • Texas Oncology, P.A. - Sherman

    Sherman, Texas

  • Baylor Scott & White Health

    Temple, Texas

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • Virginia Oncology Associates - Hampton

    Norfolk, Virginia

  • Northwest Medical Specialties, PLLC

    Tacoma, Washington

  • University of Wisconsic Hospital and Clinic

    Madison, Wisconsin

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • UZ Antwerpen

    Edegem, Belgium

  • AZ Sint-Lucas - Campus Sint-Lucas

    Ghent, Belgium

  • AZ Groeninge Campus Loofstraat

    Kortrijk, Belgium

  • AZ Delta

    Roeselare, Belgium

  • Rigshospitalet

    Copenhagen, Denmark

  • Groupe Hospitalier Pitie-Salpetriere

    Paris, France

Showing 40 of 96 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.